The market bounced back Monday after a rough week last week. We are not out of the woods yet as a huge CPI report looms on ...

Repurchase of Common & Preferred Stk. Repurchase of Common & Preferred Stk.

among people with RET fusion-positive non-small cell lung cancer (NSCLC). The latter is a new addition compared to the EU version of the test. Those green lights, according to Illumina ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation ...

BRUSSELS, Sept 3 (Reuters) - U.S. gene sequencing company Illumina (ILMN.O), opens new tab on Tuesday won its court fight against the European Union's investigation ...

BENGALURU: Illumina, a global leader in DNA sequencing and array-based technologies, announced it will establish a Global CapabilityCenter in Bengaluru to expand its technology workforce in ...

Though Illumina said goodbye to Grail this past summer—after butting heads for years with antitrust regulators and activist investors, while enduring heavy fines and orders to split—the ...

SAN DIEGO, Aug. 27, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ ... fusion-positive non-small-cell lung cancer (NSCLC) that may benefit from treatment with Lilly's RETEVMO® (selpercatinib).

Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomics, today announced a strategic partnership to accelerate the adoption of ...